- Home
- ESPR
as 04-18-2025 1:35pm EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 305.0M | IPO Year: | 2013 |
| Target Price: | $6.07 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.93 - $3.94 | Next Earning Date: | 05-06-2025 |
| Revenue: | $332,314,000 | Revenue Growth: | 185.66% |
| Revenue Growth (this year): | 5.17% | Revenue Growth (next year): | -10.06% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Warren Eric | ESPR | Chief Commercial Officer | Mar 18 '25 | Sell | $1.49 | 2,433 | $3,617.87 | 370,326 | |
| Koenig Sheldon L. | ESPR | President and CEO | Mar 18 '25 | Sell | $1.50 | 13,047 | $19,622.69 | 1,571,962 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Mar 18 '25 | Sell | $1.48 | 3,535 | $5,242.41 | 481,710 | |
| Warren Eric | ESPR | Chief Commercial Officer | Feb 19 '25 | Sell | $1.87 | 239 | $446.45 | 370,326 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Feb 19 '25 | Sell | $1.86 | 11 | $20.46 | 481,710 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Zacks
16 days ago
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?
GlobeNewswire
18 days ago
Esperion Appoints Robert E. Hoffman to Board of Directors
GlobeNewswire
a month ago
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
Zacks
a month ago
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
MT Newswires
a month ago
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia
GlobeNewswire
a month ago
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
Zacks
a month ago
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.